<DOC>
	<DOCNO>NCT02934438</DOCNO>
	<brief_summary>Reduced nitric oxide ( NO ) availability hallmark number cardiovascular disease ( CVD ) include peripheral artery disease ( PAD ) . The investigator test hypothesis sub-chronic NEO40™ supplementation improve vascular NO function improve intermittent claudication patient PAD . Using prospective , double blind , placebo control experimental design 30 patient , grade treadmill test perform baseline 3 month randomization , accord Skinner-Gardner protocol . Initial claudication distance ( ICD ) absolute claudication distance ( ACD ) record . Two consecutive treadmill test perform within 1 week baseline ( administration study drug ) ; 2 test perform 3 month . Functional status also assess Walking Impairment Questionnaire Health Status Survey SF-36 questionnaire ( SF-36 ) . Vascular function assess use Vendys® vascular reactivity ( endothelial function ) test ( Endothelix Inc ) . Digital pulse amplitude assess use sensor probe index finger reactive hyperemia . Blood collect measurement ( Neogenis ) plasma level nitrite nitrate baseline completion study . Based previously publish trial use NO technology , investigator predict group receive active supplement exhibit improvement claudication distance measure vascular function 3 month .</brief_summary>
	<brief_title>Effect Neo40 PAD</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>Persons least 45 year age Persons unilateral bilateral PAD confirm rest anklebrachial index ( ABI ) &lt; 0.9 Persons stable intermittent claudication previous 3 month Persons ability walk 1 12 minute treadmill . The prerandomization treadmill test limit exerciseinduced leg pain , relieve cessation test . Variability maximum walking distance 2 consecutive screening treadmill test &lt; 10 % . Persons ischemic rest pain , ulceration gangrene Persons history previous 3 month acute coronary syndrome revascularization involve peripheral coronary artery Persons major amputation Persons malignancy within previous 5 year ( except treat nonmelanoma skin cancer ) Persons proliferative retinopathy Persons uncontrolled hypertension Persons active inflammatory , infectious , autoimmune disease . Persons take take phosphodiesterase inhibitor , organic nitrate and/or hydralazine</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>nitric oxide</keyword>
	<keyword>Neo40 supplement ,</keyword>
	<keyword>exercise tolerance</keyword>
</DOC>